PRIORITI: Phase 4 study of triptorelin or active surveillance in high-risk prostate cancer

What Was Tested

Researchers studied Triptorelin in this randomized controlled trial publication.

After a diagnosis of prostate cancer, one of the current treatments is surgical removal of the prostate and its cancer from the body.

This is called radical prostatectomy.

Who Took Part

The abstract describes 226 men taking part.

The age groups tagged for this paper are middle-aged adults and older adults, men only.

Patients were monitored every 3 months for at least 36 months; the study ended when 61 BRs were observed.

How the Study Was Run

In design terms this was a randomized and open-label study.

Because people in this Triptorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Triptorelin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

PRIORITI (NCT01753297) was a prospective, open-label, randomized, controlled, phase 4 study conducted in China and Russia.

All people in the study had radical prostatectomy but only half of them were given triptorelin in the following 8 weeks.

What Was Measured

Their study involved 226 men from China and Russia and investigated whether giving triptorelin for 9 months would lead to better outcomes compared with giving no additional treatment (active surveillance).

High levels of PSA are a sign that the prostate cancer has returned.

The subject headings attached to it are Prostatic Neoplasms, Triptorelin Pamoate, Antineoplastic Agents, Hormonal, Prostatectomy, China, Adenocarcinoma and Watchful Waiting.

Author keywords: biochemical relapse‐free survival, prostate cancer, prostate‐specific antigen and radical prostatectomy.

What This Means in Plain Language

The paper is a randomized and open-label study of Triptorelin in 226 men.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Asia-Pacific journal of clinical oncology), a journal based in Australia.

More context: the Triptorelin compound page, all human trials.